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Abstract 
Objective: The first-appearing β-cell autoantibody has been shown to influence risk of type 1 
diabetes. Here, we assessed risk of autoantibody spreading to the second-appearing autoantibody 
and further progression to clinical disease in the Environmental Determinants of Diabetes in the 
Young study. 
Research Design and Methods: Eligible children with increased HLA-DR-DQ genetic risk for 
type 1 diabetes were followed quarterly from age 3 months up to 15 years for development of a 
single first-appearing autoantibody (GADA, IAA or IA-2A) and subsequent development of a 
single second-appearing autoantibody and progression to type 1 diabetes. Autoantibody 
positivity was defined as positivity for a specific autoantibody at two consecutive visits 
confirmed in two laboratories.  ZnT8A was measured in children who developed another 
autoantibody. 
Results: There were 608 children who developed a single first-appearing autoantibody (IAA, 
n=282 or GADA, n=326) with a median follow-up of 12.5 years from birth. The risk of a 
second-appearing autoantibody was independent of GADA versus IAA as a first-appearing 
autoantibody (adjusted-HR=1.12, 95%CI=0.88-1.42, P=0.36). Second-appearing GADA, IAA, 
IA-2A or ZnT8A conferred an increased risk of type 1 diabetes compared to children who 
remained single autoantibody positive (IAA- or GADA-second: adjusted-HR=6.44 95%CI=3.78-
10.98; IA-2A-second: adjusted-HR=16.33 95%CI=9.10-29.29, P<0.0001; ZnT8A-second: 
adjusted-HR=5.35 95%CI=2.61-10.95, P<0.0001).  In children who developed a distinct second 
autoantibody, IA-2A (adjusted-HR=3.08 95%CI=2.04-4.65, P<0.0001) conferred a greater risk 
of progression to type 1 diabetes as compared to GADA or IAA. Additionally, both a younger 
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initial age at seroconversion and shorter time to the development of the second-appearing 
autoantibody increased the risk for type 1 diabetes. 
Conclusions: The hierarchical order of distinct autoantibody spreading was independent of the 
first-appearing autoantibody type, age-dependent and augmented the risk of progression to type 1 
diabetes.  
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β-cell autoantibodies are predictors of type 1 diabetes (1; 2) and, currently, the most 
reliable indicator of pre-clinical disease. The presence of two or more autoantibodies against the 
four major autoantigens (insulin, glutamate decarboxylase, insulinoma-associated protein 2 and 
zinc transporter-8) have been shown to confer the highest risk of type 1 diabetes and was 
recently defined as Stage 1 type 1 diabetes (3). β-cell autoantibodies develop prior to and usually 
persist over time in the progression to clinical onset of type 1 diabetes (Stage 3). The age at 
appearance of specific β-cell autoantibodies varies (4-6). Autoantibodies to glutamate 
decarboxylase (GADA) or insulin (IAA) predominate as first-appearing autoantibodies (7; 8). 
IAA appearance peaks within the first 2 years of life. In contrast, GADA appears between ages 
3-5 years in children with either increased genetic risk or family history of type 1 diabetes (7-9). 
Insulinoma-associated protein 2 (IA-2A) and zinc transporter-8 (ZnT8A) autoantibodies 
generally appear after the initial islet autoantibody seroconversion (6; 8; 10; 11) in more 
advanced stages of the disease process (3; 12-14).  
Recent studies have focused on the appearance of the first-appearing autoantibody (7; 8) 
with limited discussion of the specific second-appearing autoantibody (8). The Finnish Type 1 
Diabetes Prediction and Prevention (DIPP) study (8) reported that IAA as a second-appearing 
autoantibody peaked in the first five years of life and followed a similar pattern to first-appearing 
GADA; whereas, GADA peaked within the first two years of life and mostly occurred after IAA. 
More recently, the DIPP study reported that the initial age at seroconversion was only associated 
with IAA-initiated seroconversion and further progression to type 1 diabetes (15). However, due 
to a varied autoantibody screening interval, further exploration after the first two years of life 
was limited. Other studies assessing the presence of autoimmunity and combinations of 
autoantibodies were carried out where the actual order of appearance could not be distinguished 
 5 
 
due to annual screening (16; 17) or capture was at the time of or just prior to diagnosis (1; 11; 
18-22). These previous studies assessing risk from single to multiple autoantibody showed 
increased risk was associated with a younger age, HLA-DR-DQ and IAA as first-appearing 
autoantibody (16; 17).  In addition to HLA class II risk, a recent study from the Belgian Diabetes 
Registry (23) reported that specific HLA class I alleles accelerated progression from multiple 
autoantibody positivity to type 1 diabetes in those <40 years with a family history of type 1 
diabetes. Specifically, HLA-A*24 was associated with an accelerated progression in HLA-DQ8+ 
relatives who developed either IA-2A or ZnT8A; whereas, HLA-B*18 was associated with 
accelerated progression in HLA-DQ2+ relatives who developed both IAA and GADA (23). 
Moreover, non-HLA single nucleotide polymorphisms (SNP), such as those in the INS-VNTR 
gene region (rs1004446) and protein tyrosine phosphatase non-receptor type 22 (PTPN22, 
rs2476601) have been shown to associate with a decreased and increased risk of progression to 
islet autoimmunity and type 1 diabetes, respectively (24; 25). Thus, understanding the order and 
time of appearance of each distinct autoantibody will allow for better stratification of risk.  
The aims of this study were 1) to assess the risk of developing a distinct second islet 
autoantibody in children at increased genetic risk for type 1 diabetes who newly seroconverted 
for either IAA-only or GADA-only as first-appearing autoantibodies; and, 2) to determine the 
risk associated with the specific target of the first- and second-appearing autoantibody 
combination on further progression to clinical type 1 diabetes.  
Research Design and Methods  
Study population. The Environmental Determinants of Diabetes in the Young (TEDDY) is a 
prospective cohort study of children at increased genetic risk for type 1 diabetes funded by the 
National Institutes of Health. The TEDDY study seeks to identify environmental causes of type 1 
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diabetes. There are six clinical research centers - three in the US: Colorado, Georgia/Florida, 
Washington and three in Europe: Finland, Germany, and Sweden. The high-risk genotypes for 
subjects screened from the general population with no family history of type 1 diabetes (89%) 
were as follows: DRB1*04-DQA1*03-DQB1*03:02/DRB1*03-DQA1*05-DQB1*02:01 
(DR3/4-Q2/8), DRB1*04-DQA1*03-DQB1*03:02/DRB1*04-DQA1*03-DQB1*03:02 (DR4/4-
DQ8/8), DRB1*04-DQA1*03-DQB1*03:02/DRB1*08-DQA1*04-DQB1*04:02 (DR4/8-
DQ8/4) and DRB1*03-DQA1*05-DQB1*02:01/DRB1*03-DQA1*05-DQB1*02:01 (DR3/3-
DQ2/2) and six additional genotypes in first degree relatives (FDR) of those with a family 
history of type 1 diabetes as previously described (26).  There were 8,676 children enrolled from 
September 2004 to February 2010 and currently followed prospectively from age 3 months to 15 
years with study visits every 3 months until 4 years and every 3 or 6 months, thereafter, 
depending on autoantibody positivity. All children who are persistent positive for any 
autoantibody are followed every 3 months until the age of 15 years or onset of type 1 diabetes. 
Detailed study design and methods have been published previously (26-28). The protocol was 
approved by Institutional Review Boards at participating centers and all participants provided 
written informed consent before participation in the genetic screening and enrollment.  
β-cell Autoantibodies. β-cell autoantibodies to IAA, GADA or IA-2A were measured in two 
laboratories by radiobinding assays (27; 29). In the U.S., all sera were assayed at the Barbara 
Davis Center for Childhood Diabetes at the University of Colorado Denver; in Europe, all sera 
were assayed at the University of Bristol, in the U.K. Both laboratories reported high sensitivity, 
specificity, and concordance (29; 30). All positive β-cell autoantibodies and 5% of negative 
samples were re-tested in the other reference laboratory and deemed confirmed if concordant. 
Autoantibody positivity (persistent confirmed) was defined as specific autoantibody presence on 
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≥2 consecutive visits 3 months apart and confirmed in two TEDDY laboratories. The date of 
positivity was the draw date of the first sample of the two consecutive positive samples which 
deemed a child persistent confirmed positive for a specific autoantibody. Age of seroconversion 
was the age of the child on the initial date of seroconversion to the first persistent confirmed 
autoantibody.  Age of second autoantibody seroconversion was the age of the child on the date of 
autoantibody seroconversion of a second persistent confirmed autoantibody.  Stage 1 type 1 
diabetes was defined as presence of multiple autoantibodies (3). Symptomatic type 1 diabetes 
(Stage 3) was defined according to American Diabetes Association criteria for diagnosis (3; 31). 
There were 8,502 of the 8,676 children eligible for this analysis; 174 were ineligible for this 
analysis and excluded due to not having an autoantibody test result (n=54) or were deemed 
HLA-DR-DQ ineligible based on study criteria (n=120) (Supplemental Figure S1, 
Supplemental Table S1).  As the focus of this analysis was to examine autoantibody spreading, 
the analyses were restricted to the development of the first-appearing IAA-single (n=282) or 
GADA-single (n=326) as of 31 December 2018 and followed through 31 December 2019; 
excluding children who developed multiple autoantibodies (> 2 autoantibodies) at their initial 
seroconversion (n=156) or IA-2A-only (n=15), or ZnT8A-only (n=12). There were 608 children 
included in these analyses. 
Zinc transporter 8 autoantibodies. ZnT8A radioimmunoassay was performed as previously 
described (19). The ZnT8 protein was produced by in vitro transcription and translation 
(Promega TNT kit, Madison, WI) and labeled with [35S]methionine (Perkin Elmer, Waltham, 
MA). [35S]ZnT8 (20,000 cpm) was mixed and incubated overnight at 4 °C with 2 µl of serum in 
an assay buffer (20 mM Tris HCl, pH 7.4, supplemented with 150 mM NaCl, 0.1% (w/v) BSA, 
0.15% (v/v) Tween-20 and 0.1% (w/v) sodium azide) at a final 1:25 dilution. Autoantibody-
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bound antigen was precipitated with 25 µl of 50% protein A-Sepharose (GE HealthCare, 
Piscataway, NJ) in an opaque 96-well filtration plate (Corning, Tewksbury, MA) and washed 
with two cycles of four washes per each cycle of cold assay buffer using a vacuum-operated 96-
well plate washer (BioTek, Winooski, VT). After washing, scintillation fluid, MicroScint-20 
(Perkin Elmer, Waltham, MA), was added directly to the 96-well plate, and radioactivity was 
counted on a TopCount 96-well plate -counter (Perkin Elmer, Waltham, MA). The results are 
expressed as an index (index = (sample CPM – negative control CPM)/(positive control CPM – 
negative control CPM).  The upper limit of normal (0.020) was established as the 99th percentile 
from receiver operating characteristic curves in 100 healthy control subjects and 50 patients with 
new onset diabetes. In the most recent Islet Autoantibody Standardization Program (2017) 
workshop, the sensitivity and specificity were 66 and 100%, respectively. ZnT8A was run on all 
available samples at the TEDDY Barbara Davis Laboratory, if a child was deemed antibody 
positive for IAA, GADA and/or IA-2A (any number of autoantibodies, any autoantibody, 
persistence or confirmation not required) at a visit. Persistent ZnT8A was defined as the presence 
of ZnT8A on ≥2 consecutive visits 3 months apart in a single laboratory.  Protocol compliance 
for measurement of ZnT8A prior to the first autoantibody positive sample in children with 
persistent IAA, IA-2A or GADA was 99%. For children who did not meet protocol compliance 
(n=9), the median months following the first autoantibody positive sample was 3.7 months. 
Statistical Analysis. Cumulative incidence of the appearance of the second autoantibody and the 
risk of progression to type 1 diabetes were examined in Kaplan-Meier analyses. Multivariable 
proportional hazards (PH) models were applied to assess both the cause-specific risk of 
autoantibody spreading to a second-appearing autoantibody and the risk of progression to type 1 
diabetes from the second-appearing autoantibody.   Each specific second-appearing autoantibody 
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was also examined as a time-varying predictor on risk of type 1 diabetes. To ensure that the 
second-appearing autoantibody was compared to single autoantibody positive children in each 
risk set, the other single second-appearing autoantibodies or multiple second-appearing 
autoantibodies (two autoantibodies appearing during the same 3-month interval) were censored 
at the time of their appearance as defined above. The strength of the associations with type 1 
diabetes was described by hazard ratios (HRs) and with second-appearing autoantibodies by 
cause-specific hazard ratios (CHRs) with 95% confidence intervals (CIs).  All multivariable 
analyses were adjusted for HLA-DR-DQ, gender, family history of type 1 diabetes, age at initial 
seroconversion, and first-appearing autoantibody (IAA or GADA). The following also 
considered for adjustment (and remained in the final model if P <0.10) were HLA Class I alleles 
(HLA-A*24:X, -B*18:X:X) (23), SLC30A8 (rs13266634) (32), SNPs previously shown to be 
associated with islet autoimmunity and  type 1 diabetes in TEDDY (INS (rs1004446), PTPN22 
(rs2476601), ERBB3 (rs2292239), SH2B3 (rs3184504), TNFAIP3 (rs2327832), rs1534422, 
rs10517086) (5; 24; 25; 33), and characteristics found to be associated with islet autoimmunity 
and type 1 diabetes (34-37), unless otherwise stated. Country of residence was included in all 
models as a stratified variable. Adjustments for population stratification were made by using the 
top two principal components from the Immunochip SNP data as covariates in the PH model 
(38). Data were analyzed using the Statistical Analysis System Software (Version 9.4, SAS 
Institute, Cary, NC) and GraphPad PRISM 7.04 (GraphPad Software Inc., San Diego, CA) for 
figures.  Two-tailed P values less than 0.05 were considered significant.  
Results  
 As of 31 December 2018, 608 of the 8,502 enrolled children with HLA-DR-DQ genetic 
risk for type 1 diabetes in TEDDY developed a single positive IAA or GADA at their initial 
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seroconversion and met the inclusion criteria for this analysis: IAA-only (n=282), GADA-only 
(n=326).  Of those who developed first-appearing IAA- or GADA-only (n=608), 272 (44.7%) 
remained single autoantibody positive for the duration of follow-up through 31 December 2019 
and 10.3% (n=28/272) of these single positive children progressed to type 1 diabetes within 0.95 
(0.28-3.37) years; 55.3% (n=336/608) developed another autoantibody(s) and 53.0% 
(n=178/336) of these children progressed to type 1 diabetes within 3.53 (1.56-5.83) years.  The 
median (interquartile range (IQR)) age at initial GADA- or IAA-only seroconversion was 4.28 
(2.27-7.51) and 1.83 (1.00-3.82) years, respectively. The median (IQR) follow-up from the initial 
seroconversion was 5.7 (3.2-8.7) years with the majority (98%) followed for >2 years.  
Time from first- to second-appearing autoantibody 
The characteristics of the children by specific second-appearing autoantibody are shown 
in Supplemental Table S2 and the age descriptive patterns of the second-appearing 
autoantibody are shown in Supplemental Figure S2. GADA as a second-appearing 
autoantibody developed at a median (IQR) of 3.7 (3.0-9.7) months after the first-appearing 
autoantibody, IAA as second-appearing autoantibody developed at a median of 5.9 (3.0-25.9) 
months, IA-2A as a second-appearing autoantibody developed at a median of 6.9 (3.7-17.6) 
months, and ZnT8A as a second-appearing autoantibody developed at a median of 13.3 (6.3-
23.7) months after the first-appearing autoantibody. The overall median (Q1-Q3) months after 
the first-appearing autoantibody to the appearance of the second autoantibody was 6.8 (3.2-17.0). 
There was no significant difference in the time from the first- to second-appearing autoantibody 
by the type of first-appearing IAA or GADA, taking into account the age at the initial 
seroconversion. 
Risk factors associated with development of a second-appearing autoantibody 
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Known type 1 diabetes risk factors were examined for univariate association with 
developing a second autoantibody, Supplemental Table S3. Family history of type 1 diabetes 
was positively associated with the development of a second autoantibody; while, having a minor 
allele in INS-VNTR gene region (rs1004446) or HLA-DR3/3 was inversely associated with 
developing IAA or GADA as a second autoantibody. Age at initial seroconversion was inversely 
associated with the development of a second autoantibody in multivariable analyses, Table 1. Of 
interest, the risk of developing a second autoantibody declined with increasing age at initial 
seroconversion (for each additional month older, adjusted-HR=0.986, 95%CI=0.983-0.990, P 
<0.0001). 
From the time of the first-appearing autoantibody, the risk of appearance of any second 
autoantibody did not differ if GADA or IAA was the first-appearing autoantibody (adjusted-
HR=1.12, 95%CI=0.88-1.42, P=0.36), independent of age at initial seroconversion. Further 
assessment did not find any specific second autoantibody associated with a specific first-
appearing autoantibody (IAA or GADA) after the Bonferroni correction for significance at 
P<0.008 for multiple comparisons,  Figure 1, Panels A and B. Overall, there was no significant 
difference based on either GADA-only or IAA-only as the first-appearing autoantibody on the 
risk of developing IA-2A (adjusted-CHR=1.23, 95%CI=0.69-2.20, P=0.48) or ZnT8A (adjusted-
CHR=1.62, 95%CI=0.91-2.86, P=0.09) as a second-appearing autoantibody. 
Influence of a second autoantibody on risk of progression to type 1 diabetes 
We next asked if the appearance of the second autoantibody (time-varying predictor) 
from the time of the first-appearing autoantibody influenced progression to type 1 diabetes. 
Children who developed a distinct second-appearing autoantibody had an increased risk of 
progression to type 1 diabetes as compared to children who remained single autoantibody 
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positive (IAA- or GADA-second: adjusted-HR=6.44 95%CI=3.78-10.98, P<0.0001; IA-2A-
second: adjusted-HR=16.33 95%CI=9.10-29.29, P<0.0001; ZnT8A-second: adjusted-HR=5.35 
95%CI=2.61-10.95, P<0.0001) from age of first-appearing autoantibody, adjusting for age at 
initial seroconversion, sex, family history of type 1 diabetes, HLA-DR-DQ, INS-VNTR gene 
region (rs1004446) and type of first-appearing autoantibody. No other HLA Class I alleles or 
non-HLA SNPs assessed were found to significantly associate with developing a specific second 
autoantibody. 
Risk factors associated with type 1 diabetes in children with multiple autoantibodies 
In children who developed multiple autoantibodies, IA-2A, as a second-appearing 
autoantibody, conferred a significantly greater risk of progression to type 1 diabetes (adjusted-
HR=3.08 95%CI=2.04-4.65, P<0.0001; Table 2, Figure 2) as compared to IAA or GADA. 
There was no statistical evidence that the appearance of ZnT8A as a second autoantibody as 
compared to IAA or GADA modified risk of progression to type 1 diabetes (adjusted-HR=0.81, 
95%CI=0.51-1.29, P=0.37). Other covariates significantly associated with progression in 
children who developed multiple autoantibodies were age at the appearance of the first 
autoantibody (adjusted-HR=0.98, 95%CI=0.97-0.99), P=0.001), time in months from the first to 
second autoantibody (adjusted-HR=0.97, 95%CI=0.96-0.99, P=0.003), and sex of the child 
(female versus male, adjusted-HR=1.52, 95%CI=1.09-2.13, P=0.014). Further assessment of 
specific HLA class I alleles and non-HLA SNPs (including interactions) previously shown to be 
associated with type 1 diabetes were not found significantly associated with progression in this 
population with increased HLA-DR-DQ genetic risk. 
Time effect of first- to second-appearing autoantibody on risk of type 1 diabetes 
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Finally, we examined if the time duration between the first and second autoantibody 
influenced the risk of progression to type 1 diabetes after the development of the second 
autoantibody. The risk of progression from the second-appearing autoantibody to type 1 diabetes 
declined with increasing time duration in months between the first- and second-appearing 
autoantibody (for every additional month longer, adjusted-HR=0.97, 95%CI=0.96-0.99, 
P=0.006) (Table 2). Such that, there was a 2-fold increased risk of progression to type 1 diabetes 
in children who developed a second autoantibody within 1 year of their first-appearing 
autoantibody as compared to those who developed it after 1 year post initial seroconversion 
(adjusted-HR=2.24 95%CI=1.45-3.46, P=0.0003).  
Discussion  
 In this large cohort of children at increased genetic risk for type 1 diabetes with either 
IAA or GADA as a first-appearing autoantibody, we found that the appearance of a second 
autoantibody, regardless of type, conferred at least a 5-fold increased risk of progression to type 
1 diabetes as compared to children who remained single autoantibody positive. This increased 
risk of progression varied by type of second-appearing autoantibody with IA-2A conferring the 
highest risk as compared to GADA, IAA or ZnT8A and was altered by how rapid the second 
autoantibody appeared. Development within one year doubled the risk of progression to type 1 
diabetes. Furthermore, a younger age at the initial seroconversion increased the risk of 
developing a second autoantibody and type of second-appearing autoantibody was independent 
of type of first-appearing autoantibody. Our results showed that having a family member with 
type 1 diabetes at time of screening (sibling, father or mother) was associated with the risk of a 
specific second autoantibody. And, carrying HLA-DR3/3 or the minor allele in rs1004446, a 
SNP in the INS-VNTR gene region, decreased the chance of IAA or GADA as a second-
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appearing autoantibody. Knowing the type of second autoantibody and how quickly it develops 
would increase our ability to identify subjects who are more likely to have a rapid versus slow 
progression to type 1 diabetes.  
The strengths of this study include the ability to assess risk of the appearance of another 
autoantibody and the temporal impact of this second autoantibody after the time of initial 
seroconversion. Previous studies have focused on assessing the risk of combinations of 
autoantibodies in cross-sectional screening designs when actual timing of initial seroconversion 
was unknown or in longitudinal studies with varied screening intervals or at/near diagnosis with 
type 1 diabetes in those with familial risk. The relatively short interval for autoantibody 
screening in this study captured the sequential time of autoantibody appearance in TEDDY 
children from both the general population (89%) and those with a family history.  
The majority of TEDDY children (77%) developed first-appearing IAA or GADA very 
early in life (7), as also observed in the Finnish DIPP study (8). Consistent with other studies (6; 
8; 9), both IA-2A and ZnT8A were less likely to be a first-appearing autoantibody. Overall, 
ZnT8A appeared around a median of 3-4 years of age in the BABYDIAB (11) and 4-5 years of 
age in TEDDY, a difference likely due to the predominance of first degree relatives in the former 
and a general population with increased genetic risk in the latter. The reason for this later 
appearance of ZnT8A is not clear; however, previous studies have reported that ZnT8A is 
frequently detected in those who progress to type 1 diabetes more slowly (21; 39). In TEDDY, 
GADA or IAA were more likely to present as a second-appearing autoantibody in children under 
10 years of age. It cannot be excluded that the perceived delay in the appearance of a specific 
second autoantibody as it relates to the age when the first autoantibody was triggered could mark 
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a more environmentally driven, such as a prolonged enterovirus infection (40), as compared to a 
genetically driven disease process.  
Unlike IAA, GADA and IA-2A, questions remain as to how much ZnT8A contributes to 
risk of Stage 3 type 1 diabetes, particularly in those who are young with increased genetic risk. 
In this study, ZnT8A conferred a 5-fold greater risk of progression to type 1 diabetes as 
compared to those autoantibody positive children who did not develop multiple autoantibodies. It 
is evident from our finding and other studies that ZnT8A can stratify risk of type 1 diabetes 
progression in familial risk (11; 14; 32), ethnically diverse (41), and young, high genetic risk 
populations with or without familial risk (TEDDY).  However, a large study of ICA-positive 
relatives of type 1 diabetes probands did not find ZnT8A a contributing marker of type 1 diabetes 
in those <20 years at increased genetic risk (22).  The likely reason for this inconsistency with 
our finding may be due to the preference of IAA, GADA or IA-2A over ZnT8A in those with 
familial and genetic risk, the use of cytoplasmic islet cell autoantibodies vs. IAA, GADA and IA-
2A in risk determination, the high degree of concordance between GADA and ICA and the small 
number (n=69) of subjects with increased genetic risk less than 20 years of age (22). 
Understanding the transition from single autoantibody positive to Stage 1 (multiple 
autoantibodies) has both research and clinical implications. It has been shown in multiple studies 
that the first-appearing autoantibody is age-dependent and likely associates with different 
environmental triggers (5; 7-9; 33). Assessment of previously published environmental risk 
factors (34-37) shown to associate with the induction of islet autoimmunity in TEDDY were not 
found to be involved in further development of a second autoantibody. We, therefore, suggest 
that an environmental factor(s), such as prolonged viral shedding (40), may be sought as the 
aetiological agent for the autoimmune reaction that is triggering the appearance of the first 
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autoantibody and thereby the commencement of the autoimmune pathogenesis. The present 
analysis suggests that the appearance of a second autoantibody is related to other yet unknown 
mechanisms often referred to as epitope spreading. The present data expand our understanding of 
the temporal pattern by which the second autoantibody appears. Although the mechanisms need 
to be clarified, at least it improves prediction of progression to type 1 diabetes, which advances 
our clinical practices for those at greatest risk and recruitment to secondary prevention clinical 
trials (42). Ultimately, this will result in better age-dependent autoantibody screening 
approaches, a reduction in symptomatic diagnoses and more strategic treatment interventions. 
Such specific autoantibody risk profiling will reduce heterogeneity and improve selection criteria 
to evaluate study objectives and interventions. 
The main limitations are the select high HLA-DR-DQ genetic risk population, lack of 
extended follow-up past the age of 10 years and the screening protocol for ZnT8A, which only 
measured ZnT8A in those children who developed another autoantibody (GADA, IA-2A or 
IAA) further limiting our ability to determine the incidence of ZnT8A as a first appearing 
autoantibody. A potential weakness of the present study is the inclusion criteria of children in 
four different countries with increased genetic risk for diabetes (26). The HLA-DR-DQ 
genotypes included 4-7.5% of newborns. However, the expected number of children reaching 
type 1 diabetes by 18 years of age would represent less than 50% of the total number of children 
developing type 1 diabetes. Certain HLA-DQ haplotypes, such as DQ5.1 and DQ6.4 are missing 
from the TEDDY cohort. It cannot be excluded that the pattern of IA-2A and ZnT8A as a 
second-appearing autoantibody may differ from the present observations.  
Taken together, in children less than 10 years of age with genetic risk for type 1 diabetes, the 
type of second-appearing autoantibody was associated with both genetic and familial risk, as 
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well as, varying risks of progression to type 1 diabetes. All four autoantibodies under study 
increased the risk of Stage 3 type 1 diabetes. Age continues to play a critical role in the initiation 
of autoimmunity, development of multiple autoantibodies and progression to type 1 diabetes. 
The importance of understanding what triggers epitope spreading and the type of autoantibody is 
critical in prevention of disease progression. Further analyses including the adolescent years 
(>10 years) are required to better understand the transition to Stage 1 (multiple autoantibodies) 
and how it affects risk of Stage 3 type 1 diabetes, especially, in a more diverse general 
population with low to medium genetic risk.    
Figure Legends 
Figure 1. Cumulative incidence in children with distinct single first-appearing autoantibody 
positivity (IAA or GADA) for progression to distinct single second-appearing autoantibody 
positivity. Panel A shows the cumulative incidence of the second-appearing autoantibody by 
months since first-appearing IAA. Panel B shows the cumulative incidence of the second-
appearing autoantibody by months since first-appearing GADA. The blue line represents IAA, 
black line represents GADA, red line represents IA-2A and green line represents Znt8A. 
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Figure 2. Cumulative incidence in children with a distinct single second-appearing autoantibody 
for progression to type 1 diabetes (blue line represents GADA or IAA, red line represents IA-2A, 
and green line represents ZnT8A). The black dotted horizontal line is the 5 year (60 month) 
cumulative risk of type 1 diabetes among the children who remained single autoantibody 
positive. The median (IQR) time between the first- and second-appearing autoantibody 
seroconversions was 5.3(3.0-13.3) months for GADA or IAA, 6.9(3.7-17.6) months for IA-2A, 
and 13.3(6.3-23.7) months for ZnT8A. 
 
Author Contributions: All authors attest to meeting ICMJE uniform requirements for 
authorship by making substantial contributions to conception and design of this paper, 
acquisition, analysis and interpretation of the data, drafting or revising the article for intellectual 
content, and giving final approval of the published version. K.V. designed the study, proposed 
 19 
 
the analysis, performed the analysis and contributed to the manuscript, interpreted the findings, 
and wrote the manuscript. Å.L., E.B., J.K. designed the study, interpreted the findings and 
reviewed/edited manuscript. J-X.S., J.T., A.Z., W.H., D.S., M.R. and B.A. designed the study 
and reviewed/edited manuscript. L.Y. A.W. reviewed/edited manuscript.  K.V. is the guarantor 
of this work and, as such, had full access to all the data in the study and takes responsibility for 
the integrity of the data and the accuracy of the data analysis. 
Acknowledgments: The authors thank Sarah Austin-Gonzalez with the Health Informatics 
Institute at the University of South Florida for assistance with preparing the figures. 
A special acknowledgement to the TEDDY families for their continued participation in this 
wonderful study.  
Funding: Funded by U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 
DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 
DK63865, UC4 DK63863, UC4 DK63836, UC4 DK95300, UC4 DK100238, UC4 DK106955, 
UC4 DK112243, UC4 DK117483, and Contract No. HHSN267200700014C from the National 
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy 
and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and 
Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), 
Juvenile Diabetes Research Foundation (JDRF), and Centers for Disease Control and Prevention 
(CDC). This work supported in part by the NIH/NCATS Clinical and Translational Science 
Awards to the University of Florida (UL1 TR000064) and the University of Colorado (UL1 
TR001082). 
Duality of interest: There are no conflicts of interest. 
 20 
 
Electronic supplementary material: A complete list of the members of the TEDDY Study Group 
can be found in the online version of this article. 
A portion of this work was presented at the Immunology of Diabetes Society Meeting, London, 
UK on October 27th, 2018. 
References 
 
1. Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA: Prediction of IDDM in the 
general population: strategies based on combinations of autoantibody markers. Diabetes 1997;46:1701-
1710 
2. Bonifacio E, Bingley PJ: Islet autoantibodies and their use in predicting insulin-dependent diabetes. 
Acta Diabetol 1997;34:185-193 
3. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, 
Krischer JP, Lernmark A, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG: 
Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the 
American Diabetes Association. Diabetes Care 2015;38:1964-1974 
4. Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer JP: 
Development of autoantibodies in the TrialNet Natural History Study. Diabetes Care 2011;34:1897-1901 
5. Krischer JP, Liu X, Vehik K, Akolkar B, Hagopian WA, Rewers MJ, She JX, Toppari J, Ziegler AG, 
Lernmark A, Group TS: Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-Year TEDDY 
Study Progress Report. Diabetes Care 2019;42:1051-1060 
6. Ziegler AG, Hummel M, Schenker M, Bonifacio E: Autoantibody appearance and risk for development 
of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German 
BABYDIAB Study. Diabetes 1999;48:460-468 
7. Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark A, Hagopian WA, Rewers MJ, She JX, Simell 
OG, Toppari J, Ziegler AG, Akolkar B, Bonifacio E: The 6 year incidence of diabetes-associated 
autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 2015;58:980-987 
8. Ilonen J, Hammais A, Laine AP, Lempainen J, Vaarala O, Veijola R, Simell O, Knip M: Patterns of 
beta-cell autoantibody appearance and genetic associations during the first years of life. Diabetes 
2013;62:3636-3640 
9. Ziegler AG, Bonifacio E, Group B-BS: Age-related islet autoantibody incidence in offspring of patients 
with type 1 diabetes. Diabetologia 2012;55:1937-1943 
10. Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS, Davidson HW, Hutton JC: 
SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in 
prediabetes. Ann N Y Acad Sci 2008;1150:256-259 
11. Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, Winkler C, Pfluger M, 
Illig T, Bonifacio E, Ziegler AG: Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify 
type 1 diabetes risk. Diabetologia 2009;52:1881-1888 
12. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, 
Knip M, Bonifacio E, Eisenbarth GS: Seroconversion to multiple islet autoantibodies and risk of 
progression to diabetes in children. JAMA 2013;309:2473-2479 
13. Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C, Chase P, Klingensmith G, Erlich H, 
Norris J, Eisenbarth GS: Antiislet autoantibodies usually develop sequentially rather than simultaneously. 
J Clin Endocrinol Metab 1996;81:4264-4267 
14. De Grijse J, Asanghanwa M, Nouthe B, Albrecher N, Goubert P, Vermeulen I, Van Der Meeren S, 
Decochez K, Weets I, Keymeulen B, Lampasona V, Wenzlau J, Hutton JC, Pipeleers D, Gorus FK, 
Belgian Diabetes R: Predictive power of screening for antibodies against insulinoma-associated protein 2 
 21 
 
beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk 
of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 
2010;53:517-524 
15. Bauer W, Veijola R, Lempainen J, Kiviniemi M, Harkonen T, Toppari J, Knip M, Gyenesei A, Ilonen 
J: Age at Seroconversion, HLA Genotype, and Specificity of Autoantibodies in Progression of Islet 
Autoimmunity in Childhood. J Clin Endocrinol Metab 2019;104:4521-4530 
16. Gorus FK, Balti EV, Messaaoui A, Demeester S, Van Dalem A, Costa O, Dorchy H, Mathieu C, Van 
Gaal L, Keymeulen B, Pipeleers DG, Weets I, Belgian Diabetes R: Twenty-Year Progression Rate to 
Clinical Onset According to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-Based 
Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes. Diabetes Care 
2017;40:1065-1072 
17. Bingley PJ, Boulware DC, Krischer JP, Type 1 Diabetes TrialNet Study G: The implications of 
autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other 
autoantibodies and progression to type 1 diabetes. Diabetologia 2016;59:542-549 
18. Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJ, Bingley PJ, Bonifacio E, Ziegler AG: 
Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 
2004;53:384-392 
19. Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, 
Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL, Type 1 Diabetes TrialNet Study G: Zinc transporter-8 
autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical 
autoantibodies. Diabetes Care 2012;35:1213-1218 
20. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP, Schatz D, 
Eisenbarth G: Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention 
Trial-Type 1. Diabetes Care 2009;32:2269-2274 
21. Long AE, Gooneratne AT, Rokni S, Williams AJ, Bingley PJ: The role of autoantibodies to zinc 
transporter 8 in prediction of type 1 diabetes in relatives: lessons from the European Nicotinamide 
Diabetes Intervention Trial (ENDIT) cohort. J Clin Endocrinol Metab 2012;97:632-637 
22. Long AE, Gillespie KM, Rokni S, Bingley PJ, Williams AJ: Rising incidence of type 1 diabetes is 
associated with altered immunophenotype at diagnosis. Diabetes 2012;61:683-686 
23. Balke EM, Balti EV, Van der Auwera B, Weets I, Costa O, Demeester S, Abrams P, Casteels K, 
Coeckelberghs M, Tenoutasse S, Keymeulen B, Pipeleers DG, Gorus FK, Belgian Diabetes R: 
Accelerated Progression to Type 1 Diabetes in the Presence of HLA-A*24 and -B*18 Is Restricted to 
Multiple Islet Autoantibody-Positive Individuals With Distinct HLA-DQ and Autoantibody Risk Profiles. 
Diabetes Care 2018;41:1076-1083 
24. Torn C, Hadley D, Lee HS, Hagopian W, Lernmark A, Simell O, Rewers M, Ziegler A, Schatz D, 
Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, Mykkanen J, Ilonen J, Rich SS, She JX, Steck 
AK, Krischer J: Role of Type 1 Diabetes-Associated SNPs on Risk of Autoantibody Positivity in the 
TEDDY Study. Diabetes 2015;64:1818-1829 
25. Torn C, Liu X, Hagopian W, Lernmark A, Simell O, Rewers M, Ziegler AG, Schatz D, Akolkar B, 
Onengut-Gumuscu S, Chen WM, Toppari J, Mykkanen J, Ilonen J, Rich SS, She JX, Sharma A, Steck A, 
Krischer J, Group TS: Complement gene variants in relation to autoantibodies to beta cell specific 
antigens and type 1 diabetes in the TEDDY Study. Sci Rep 2016;6:27887 
26. Hagopian WA, Erlich H, Lernmark A, Rewers M, Ziegler AG, Simell O, Akolkar B, Vogt R, Jr., Blair 
A, Ilonen J, Krischer J, She J, Group TS: The Environmental Determinants of Diabetes in the Young 
(TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes 
2011;12:733-743 
27. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann N Y Acad Sci 
2008;1150:1-13 
28. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr 
Diabetes 2007;8:286-298 
 22 
 
29. Bonifacio E, Yu L, Williams AK, Eisenbarth GS, Bingley PJ, Marcovina SM, Adler K, Ziegler AG, 
Mueller PW, Schatz DA, Krischer JP, Steffes MW, Akolkar B: Harmonization of glutamic acid 
decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and 
kidney diseases consortia. J Clin Endocrinol Metab 2010;95:3360-3367 
30. Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, Eisenbarth GS: Early expression of 
antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent 
diabetes. Proc Natl Acad Sci U S A 2000;97:1701-1706 
31. Association AD: Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37:S81-S90 
32. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, 
Davidson HW, Hutton JC: The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human 
type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-17045 
33. Krischer JP, Lynch KF, Lernmark A, Hagopian WA, Rewers MJ, She JX, Toppari J, Ziegler AG, 
Akolkar B, Group TS: Genetic and Environmental Interactions Modify the Risk of Diabetes-Related 
Autoimmunity by 6 Years of Age: The TEDDY Study. Diabetes Care 2017;40:1194-1202 
34. Uusitalo U, Liu X, Yang J, Aronsson CA, Hummel S, Butterworth M, Lernmark A, Rewers M, 
Hagopian W, She JX, Simell O, Toppari J, Ziegler AG, Akolkar B, Krischer J, Norris JM, Virtanen SM: 
Association of Early Exposure of Probiotics and Islet Autoimmunity in the TEDDY Study. JAMA Pediatr 
2016;170:20-28 
35. Lonnrot M, Lynch KF, Elding Larsson H, Lernmark A, Rewers MJ, Torn C, Burkhardt BR, Briese T, 
Hagopian WA, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Krischer JP, Hyoty H, Group TS: 
Respiratory infections are temporally associated with initiation of type 1 diabetes autoimmunity: the 
TEDDY study. Diabetologia 2017;60:1931-1940 
36. Elding Larsson H, Vehik K, Haller MJ, Liu X, Akolkar B, Hagopian W, Krischer J, Lernmark A, She 
JX, Simell O, Toppari J, Ziegler AG, Rewers M, Group TS: Growth and Risk for Islet Autoimmunity and 
Progression to Type 1 Diabetes in Early Childhood: The Environmental Determinants of Diabetes in the 
Young Study. Diabetes 2016;65:1988-1995 
37. Lynch KF, Lee HS, Torn C, Vehik K, Krischer JP, Larsson HE, Haller MJ, Hagopian WA, Rewers 
MJ, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Hyoty H, Bonifacio E, Lernmark A, Group 
TS: Gestational respiratory infections interacting with offspring HLA and CTLA-4 modifies incident 
beta-cell autoantibodies. J Autoimmun 2018;86:93-103 
38. Concannon P, Rich SS, Nepom GT: Genetics of type 1A diabetes. N Engl J Med 2009;360:1646-1654 
39. Long AE, Wilson IV, Becker DJ, Libman IM, Arena VC, Wong FS, Steck AK, Rewers MJ, Yu L, 
Achenbach P, Casas R, Ludvigsson J, Williams AJK, Gillespie KM: Characteristics of slow progression 
to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL 
study. Diabetologia 2018;61:1484-1490 
40. Vehik K, Lynch KF, Wong MC, Tian X, Ross MC, Gibbs RA, Ajami NJ, Petrosino JF, Rewers M, 
Toppari J, Ziegler AG, She JX, Lernmark A, Akolkar B, Hagopian WA, Schatz DA, Krischer JP, Hyoty 
H, Lloyd RE, Group TS: Prospective virome analyses in young children at increased genetic risk for type 
1 diabetes. Nat Med 2019;25:1865-1872 
41. Gomes KF, Semzezem C, Batista R, Fukui RT, Santos AS, Correia MR, Passos-Bueno MR, Silva 
ME: Importance of Zinc Transporter 8 Autoantibody in the Diagnosis of Type 1 Diabetes in Latin 
Americans. Sci Rep 2017;7:207 
42. Endesfelder D, Zu Castell W, Bonifacio E, Rewers M, Hagopian WA, She JX, Lernmark A, Toppari 
J, Vehik K, Williams AJK, Yu L, Akolkar B, Krischer JP, Ziegler AG, Achenbach P, Group TS: Time-
Resolved Autoantibody Profiling Facilitates Stratification of Preclinical Type 1 Diabetes in Children. 
Diabetes 2019;68:119-130 
 
 
 23 
 
Table 1. Multivariable cause-specific hazards ratios (CHR) in children with a single first-appearing IAA or GADA positivity (n=608) 
for progression to second autoantibody positivity (n=336ǂ). 
 
 Second-appearing autoantibody 
 GADA or IAA IA-2A ZnT8A 
  Cause-specific HR* (95% CI), P 
Female vs. Male 0.90(0.65-1.23), p=0.50 1.12(0.67-1.87), p=0.67 0.64(0.38-1.07), p=0.09 
Family History of type 1 diabetes (reference= 
no family history) 
   
Sibling with type 1 diabetes 2.22(1.12-4.40), p=0.023 0.86(0.12-6.43), p=0.89 1.93(0.57-6.48), p=0.29 
Father with type 1 diabetes 1.35(0.82-2.23), p=0.24 1.54(0.71-3.35), p=0.27 2.15(1.04-4.46), p=0.039 
Mother with type 1 diabetes 0.80(0.31-2.10), p=0.65 2.88(1.06-7.84), p=0.039 2.15(0.66-7.08), p=0.21 
HLA-DR-DQ genotype (reference=DR4/4)    
DR3/4 1.26(0.83-1.93), p=0.28 1.21(0.58-2.52), p=0.62 1.20(0.56-2.54), p=0.64 
DR4/8 0.55(0.29-1.01), p=0.05 1.74(0.76-4.01), p=0.19 1.01(0.40-2.57), p=0.98 
DR3/3 0.32(0.16-0.67), p=0.003 0.69(0.26-1.85), p=0.46 0.96(0.40-2.30), p=0.93 
First Degree Relative (FDR) Specific**  1.01(0.35-2.89), p=0.98 0.38(0.04-3.30), p=0.38 NA, p=0.98 
SNP rs1004446_A (INS) 0.70(0.51-0.96), p=0.025 0.94(0.56-1.57), p=0.81 1.03(0.62-1.72), p=0.90 
First Appearing Ab (GADA vs. IAA) 0.94(0.67-1.33), p=0.73 1.23(0.69-2.20), p=0.48 1.62(0.91-2.86), p=0.09 
Age at First Appearing Autoantibody 0.99(0.98-0.99), p<0.0001 0.98(0.97-0.99), p=0.0002 0.99(0.98-99), p=0.003 
*Stratified Cox Regression with country of residence. 
** FDR specific includes: DR4/1, DR4/9, DR4/13, DR3/9, DR4/4-DQB1*20X, DR4/4-DQB1*304. 
ǂ 47 children developed two autoantibodies within the same 3-month interval as second-appearing autoantibodies and were censored at time of second-appearing 
autoantibody positivity. Data not presented due to difficulty in determining order of appearance. 
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Table 2. Multivariable proportional hazard ratios (HR) in children with a distinct second-
appearing autoantibody (n=289) for progression to type 1 diabetes (n=149). 
 
 HR (95% CI) P 
Type of second antibody   
IAA or GADA 1 [Reference]  
IA-2A 3.08 (2.04-4.65) <0.0001 
ZnT8A 0.81 (0.51-1.29) 0.37 
Age at first-appearing autoantibody 
(months) 
0.98 (0.97-0.99) 0.001 
Time from first to second 
autoantibody (months) 
0.97 (0.96-0.99) 0.003 
Sex   
Female 1.52 (1.09-2.13) 0.014 
Male 1 [Reference]  
Family History of T1D   
Mother with T1D 1.55 (0.65-3.67) 0.32 
Father with T1D 1.01 (0.60-1.70) 0.97 
Sibling with T1D 0.92 (0.46-1.76) 0.82 
General population (no T1D history) 1 [Reference]  
HLA-DR-DQ genotype   
DR3/4 1.70 (0.99-2.93) 0.06 
DR4/4 1 [Reference]  
DR4/8 1.32 (0.69-2.54) 0.41 
DR3/3 0.97 (0.44-2.15) 0.94 
FDR-specific* 1.28 (0.35-4.63) 0.71 
Type of first antibody   
GADA only 0.97 (0.66-1.43) 0.89 
IAA only 1 [Reference]  
             *FDR specific HLA-DR-DQ genotypes are DR4/4b, DR4/1, DR4/9, DR4/13, and DR3/9. 
 
 
